FY24 consensus $2.62. Narrows FY24 revenue view to $2.08B-$2.13B from $2.06B-$2.16B, consensus $2.12B. Backs FY24 adjusted EBITDA view $368M-383M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENOV:
- ENOV Earnings this Week: How Will it Perform?
- Enovis Announces Time Change for Second Quarter 2024 Results Conference Call
- Enovis to Host Second Quarter 2024 Results Conference Call on August 7th
- Enovis releases AltiVate Reverse Glenoid System
- Enovis™ Releases AltiVate Reverse® Glenoid System, Widening Range of Patients Who May be Treated with AltiVate Reverse®